Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 전대원 | - |
dc.date.accessioned | 2017-09-08T01:57:20Z | - |
dc.date.available | 2017-09-08T01:57:20Z | - |
dc.date.issued | 2015-11 | - |
dc.identifier.citation | JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, v. 355, NO 3, Page. 362-369 | en_US |
dc.identifier.issn | 0022-3565 | - |
dc.identifier.issn | 1521-0103 | - |
dc.identifier.uri | http://jpet.aspetjournals.org/content/355/3/362 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/28978 | - |
dc.description.abstract | Liver X receptor (LXR) is a member of the nuclear receptor superfamily, and it regulates various biologic processes, including de novo lipogenesis, cholesterol metabolism, and inflammation. Selective inhibition of LXR may aid the treatment of nonalcoholic fatty liver diseases. In the present study, we evaluated the effects of three cinnamamide derivatives on ligand-induced LXR alpha activation and explored whether these derivatives could attenuate steatosis in mice. N-(4-trifluoromethylphenyl) 3,4-dimethoxycinnamamide (TFCA) decreased the luciferase activity in LXRE-tk-Luc-transfected cells and also suppressed ligand-induced lipid accumulation and expression of the lipogenic genes in murine hepatocytes. Furthermore, it significantly attenuated hepatic neutral lipid accumulation in a ligand-induced fatty liver mouse system. Modeling study indicated that TFCA inhibited activation of the LXR alpha ligand-binding domain by hydrogen bonding to Arg305 in the H5 region of that domain. It regulated the transcriptional control exerted by LXR alpha by influencing coregulator exchange; this process involves dissociation of the thyroid hormone receptor-associated proteins (TRAP)/DRIP coactivator and recruitment of the nuclear receptor corepressor. These results show that TFCA has the potential to attenuate ligand-induced lipogenesis and fatty liver by selectively inhibiting LXR alpha in the liver. | en_US |
dc.description.sponsorship | This work was supported by grants of the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A121185). | en_US |
dc.language.iso | en | en_US |
dc.publisher | AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS | en_US |
dc.subject | ELEMENT-BINDING PROTEIN-1C | en_US |
dc.subject | CINNAMIC ACID-DERIVATIVES | en_US |
dc.subject | LXR-ALPHA | en_US |
dc.subject | NUCLEAR RECEPTORS | en_US |
dc.subject | GENE-EXPRESSION | en_US |
dc.subject | INSULIN-RESISTANCE | en_US |
dc.subject | SREBP-1C | en_US |
dc.subject | AGONIST | en_US |
dc.subject | INFLAMMATION | en_US |
dc.subject | STIMULATION | en_US |
dc.title | Cinnamamides, Novel Liver X Receptor Antagonists that Inhibit Ligand-Induced Lipogenesis and Fatty Liver | en_US |
dc.type | Article | en_US |
dc.relation.no | 3 | - |
dc.relation.volume | 355 | - |
dc.identifier.doi | 10.1124/jpet.115.226738 | - |
dc.relation.page | 362-369 | - |
dc.relation.journal | JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS | - |
dc.contributor.googleauthor | Sim, Woo-Cheol | - |
dc.contributor.googleauthor | Kim, Dong Gwang | - |
dc.contributor.googleauthor | Lee, Kyeong Jin | - |
dc.contributor.googleauthor | Choi, You-Jin | - |
dc.contributor.googleauthor | Choi, Yeon Jae | - |
dc.contributor.googleauthor | Shin, Kye Jung | - |
dc.contributor.googleauthor | Jun, Dae Won | - |
dc.contributor.googleauthor | Park, So-Jung | - |
dc.contributor.googleauthor | Park, Hyun-Ju | - |
dc.contributor.googleauthor | Kim, Jiwon | - |
dc.relation.code | 2015001010 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | noshin | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.